KR101010547B1 - 알기닌아미드류를 함유하는 의약 제제 - Google Patents
알기닌아미드류를 함유하는 의약 제제 Download PDFInfo
- Publication number
- KR101010547B1 KR101010547B1 KR1020057017410A KR20057017410A KR101010547B1 KR 101010547 B1 KR101010547 B1 KR 101010547B1 KR 1020057017410 A KR1020057017410 A KR 1020057017410A KR 20057017410 A KR20057017410 A KR 20057017410A KR 101010547 B1 KR101010547 B1 KR 101010547B1
- Authority
- KR
- South Korea
- Prior art keywords
- delete delete
- solution
- group
- pharmaceutical composition
- agatroban
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 239000000825 pharmaceutical preparation Substances 0.000 title abstract description 34
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 87
- 239000004480 active ingredient Substances 0.000 claims abstract description 35
- 239000000126 substance Substances 0.000 claims abstract description 35
- 238000004519 manufacturing process Methods 0.000 claims abstract description 21
- 238000003860 storage Methods 0.000 claims abstract description 8
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 121
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 42
- 238000004090 dissolution Methods 0.000 claims description 30
- 150000005846 sugar alcohols Polymers 0.000 claims description 22
- 235000011187 glycerol Nutrition 0.000 claims description 21
- 230000001954 sterilising effect Effects 0.000 claims description 18
- 238000004659 sterilization and disinfection Methods 0.000 claims description 18
- 238000000034 method Methods 0.000 claims description 14
- 150000001720 carbohydrates Chemical class 0.000 claims description 9
- 235000000346 sugar Nutrition 0.000 claims description 9
- 150000008163 sugars Chemical class 0.000 claims description 6
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 claims description 4
- 229910052698 phosphorus Inorganic materials 0.000 claims description 4
- 239000011574 phosphorus Substances 0.000 claims description 4
- -1 arginine amides Chemical class 0.000 abstract description 75
- 239000004475 Arginine Substances 0.000 abstract description 28
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 abstract description 28
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract description 23
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract description 22
- 125000000217 alkyl group Chemical group 0.000 abstract description 16
- 150000003839 salts Chemical class 0.000 abstract description 15
- 125000003545 alkoxy group Chemical group 0.000 abstract description 8
- 125000000623 heterocyclic group Chemical group 0.000 abstract description 8
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 abstract description 8
- 229910052717 sulfur Inorganic materials 0.000 abstract description 7
- 125000004434 sulfur atom Chemical group 0.000 abstract description 7
- 125000004432 carbon atom Chemical group C* 0.000 abstract description 5
- 239000003814 drug Substances 0.000 abstract description 3
- 239000000243 solution Substances 0.000 description 92
- 239000000203 mixture Substances 0.000 description 43
- 238000002347 injection Methods 0.000 description 19
- 239000007924 injection Substances 0.000 description 19
- 239000003708 ampul Substances 0.000 description 16
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 15
- 238000009472 formulation Methods 0.000 description 13
- 150000004677 hydrates Chemical class 0.000 description 13
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 12
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 12
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical group OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 12
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 12
- 239000000600 sorbitol Substances 0.000 description 12
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 9
- 150000001875 compounds Chemical class 0.000 description 9
- 238000004128 high performance liquid chromatography Methods 0.000 description 9
- 238000002360 preparation method Methods 0.000 description 9
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 7
- 239000012153 distilled water Substances 0.000 description 7
- 239000007788 liquid Substances 0.000 description 7
- 238000003756 stirring Methods 0.000 description 7
- 239000000523 sample Substances 0.000 description 6
- 125000003277 amino group Chemical group 0.000 description 5
- 239000008215 water for injection Substances 0.000 description 5
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 239000012488 sample solution Substances 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 3
- 238000000354 decomposition reaction Methods 0.000 description 3
- 238000011049 filling Methods 0.000 description 3
- 239000011521 glass Substances 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 125000005493 quinolyl group Chemical group 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 239000012086 standard solution Substances 0.000 description 3
- 125000001424 substituent group Chemical group 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- ULEBESPCVWBNIF-BYPYZUCNSA-N L-arginine amide Chemical compound NC(=O)[C@@H](N)CCCNC(N)=N ULEBESPCVWBNIF-BYPYZUCNSA-N 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 230000000996 additive effect Effects 0.000 description 2
- 150000001298 alcohols Chemical class 0.000 description 2
- 229910021529 ammonia Inorganic materials 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 230000000052 comparative effect Effects 0.000 description 2
- 239000007857 degradation product Substances 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
- 239000003002 pH adjusting agent Substances 0.000 description 2
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- KXNPVXPOPUZYGB-IOVMHBDKSA-N (2R,4R)-1-[(2S)-5-(diaminomethylideneamino)-2-[(3-methyl-1,2,3,4-tetrahydroquinolin-8-yl)sulfonylamino]-1-oxopentyl]-4-methyl-2-piperidinecarboxylic acid Chemical compound OC(=O)[C@H]1C[C@H](C)CCN1C(=O)[C@H](CCCN=C(N)N)NS(=O)(=O)C1=CC=CC2=C1NCC(C)C2 KXNPVXPOPUZYGB-IOVMHBDKSA-N 0.000 description 1
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical compound OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 1
- UQHCHLWYGMSPJC-UHFFFAOYSA-N 4-methylpiperidin-1-ium-2-carboxylate Chemical compound CC1CCNC(C(O)=O)C1 UQHCHLWYGMSPJC-UHFFFAOYSA-N 0.000 description 1
- 0 CC(*)NS(*)(=O)=O Chemical compound CC(*)NS(*)(=O)=O 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 125000000174 L-prolyl group Chemical group [H]N1C([H])([H])C([H])([H])C([H])([H])[C@@]1([H])C(*)=O 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 241001122767 Theaceae Species 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 125000000641 acridinyl group Chemical group C1(=CC=CC2=NC3=CC=CC=C3C=C12)* 0.000 description 1
- 125000003282 alkyl amino group Chemical group 0.000 description 1
- MWPLVEDNUUSJAV-UHFFFAOYSA-N anthracene Natural products C1=CC=CC2=CC3=CC=CC=C3C=C21 MWPLVEDNUUSJAV-UHFFFAOYSA-N 0.000 description 1
- 125000005428 anthryl group Chemical group [H]C1=C([H])C([H])=C2C([H])=C3C(*)=C([H])C([H])=C([H])C3=C([H])C2=C1[H] 0.000 description 1
- 239000004019 antithrombin Substances 0.000 description 1
- 229960003856 argatroban Drugs 0.000 description 1
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 1
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 125000004106 butoxy group Chemical group [*]OC([H])([H])C([H])([H])C(C([H])([H])[H])([H])[H] 0.000 description 1
- 125000000609 carbazolyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3NC12)* 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 238000013329 compounding Methods 0.000 description 1
- 239000008380 degradant Substances 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 125000004663 dialkyl amino group Chemical group 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 125000004988 dibenzothienyl group Chemical group C1(=CC=CC=2SC3=C(C21)C=CC=C3)* 0.000 description 1
- 238000004945 emulsification Methods 0.000 description 1
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 description 1
- 125000003983 fluorenyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3CC12)* 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 125000005842 heteroatom Chemical group 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 150000007529 inorganic bases Chemical class 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000003253 isopropoxy group Chemical group [H]C([H])([H])C([H])(O*)C([H])([H])[H] 0.000 description 1
- 125000005956 isoquinolyl group Chemical group 0.000 description 1
- 238000004811 liquid chromatography Methods 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 125000004433 nitrogen atom Chemical group N* 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 125000004430 oxygen atom Chemical group O* 0.000 description 1
- 229940127557 pharmaceutical product Drugs 0.000 description 1
- 125000005561 phenanthryl group Chemical group 0.000 description 1
- 125000001791 phenazinyl group Chemical group C1(=CC=CC2=NC3=CC=CC=C3N=C12)* 0.000 description 1
- 125000001484 phenothiazinyl group Chemical group C1(=CC=CC=2SC3=CC=CC=C3NC12)* 0.000 description 1
- 125000001644 phenoxazinyl group Chemical group C1(=CC=CC=2OC3=CC=CC=C3NC12)* 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- ONMKMDRLWPHKHJ-UHFFFAOYSA-M sodium propane-1,2,3-triol chloride hydrate Chemical compound O.[Na+].[Cl-].OCC(O)CO ONMKMDRLWPHKHJ-UHFFFAOYSA-M 0.000 description 1
- 229910001220 stainless steel Inorganic materials 0.000 description 1
- 239000010935 stainless steel Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 125000001712 tetrahydronaphthyl group Chemical group C1(CCCC2=CC=CC=C12)* 0.000 description 1
- 230000024883 vasodilation Effects 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- General Chemical & Material Sciences (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Dermatology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2003077125 | 2003-03-20 | ||
| JPJP-P-2003-00077125 | 2003-03-20 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| KR20060002825A KR20060002825A (ko) | 2006-01-09 |
| KR101010547B1 true KR101010547B1 (ko) | 2011-01-24 |
Family
ID=33027937
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020057017410A Expired - Lifetime KR101010547B1 (ko) | 2003-03-20 | 2004-03-19 | 알기닌아미드류를 함유하는 의약 제제 |
Country Status (5)
| Country | Link |
|---|---|
| JP (1) | JP3781308B2 (enExample) |
| KR (1) | KR101010547B1 (enExample) |
| CN (1) | CN100344624C (enExample) |
| TW (1) | TW200505422A (enExample) |
| WO (1) | WO2004083201A1 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2006008696A (ja) * | 2003-03-20 | 2006-01-12 | Mitsubishi Pharma Corp | アルギニンアミド類を含有する医薬製剤 |
| ATE514416T1 (de) * | 2005-09-01 | 2011-07-15 | Baxter Internat Inc A Delaware Corp | Argatrobanformulierung mit einer säure als lösungsvermittler |
| JP5438999B2 (ja) * | 2009-03-19 | 2014-03-12 | テルモ株式会社 | アルガトロバン注射液製剤 |
| CN102120026A (zh) * | 2011-03-03 | 2011-07-13 | 天津市炜杰科技有限公司 | 以醇作为增溶剂的21(s)阿加曲班静脉注射液 |
| CN102228426A (zh) * | 2011-06-17 | 2011-11-02 | 天津市炜杰科技有限公司 | 以醇作为增溶剂的21(r)阿加曲班静脉注射液 |
| CN104098647B (zh) * | 2014-06-24 | 2017-12-08 | 安徽省逸欣铭医药科技有限公司 | 阿加曲班类似物及其制备方法和医药用途 |
| CN114689768A (zh) * | 2020-12-31 | 2022-07-01 | 汉寿康运医药科技有限公司 | 一种阿加曲班一水合物中杂质含量的分离检测方法 |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2002241284A (ja) * | 2001-02-16 | 2002-08-28 | Towa Yakuhin Kk | 全身投与用アルガトロバン注射液 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS6431727A (en) * | 1987-07-28 | 1989-02-02 | Mitsubishi Chem Ind | Dissolution of argininamide and drug composition containing argininamides |
| US5214052A (en) * | 1987-07-28 | 1993-05-25 | Mitsubishi Kasei Corporation | Method for dissolving arginineamides and pharmaceutical compositions containing them |
| JP3530542B2 (ja) * | 1992-03-18 | 2004-05-24 | 三菱化学株式会社 | 眼科用アルガトロバン製剤 |
| FR2715566B1 (fr) * | 1994-02-03 | 1996-03-08 | Synthelabo | Solutions aqueuses concentrées d'argatroban. |
-
2004
- 2004-03-19 CN CNB2004800076128A patent/CN100344624C/zh not_active Expired - Lifetime
- 2004-03-19 WO PCT/JP2004/003768 patent/WO2004083201A1/ja not_active Ceased
- 2004-03-19 KR KR1020057017410A patent/KR101010547B1/ko not_active Expired - Lifetime
- 2004-03-19 JP JP2005503766A patent/JP3781308B2/ja not_active Expired - Lifetime
- 2004-03-19 TW TW093107492A patent/TW200505422A/zh not_active IP Right Cessation
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2002241284A (ja) * | 2001-02-16 | 2002-08-28 | Towa Yakuhin Kk | 全身投与用アルガトロバン注射液 |
Also Published As
| Publication number | Publication date |
|---|---|
| TW200505422A (en) | 2005-02-16 |
| JPWO2004083201A1 (ja) | 2006-06-22 |
| JP3781308B2 (ja) | 2006-05-31 |
| KR20060002825A (ko) | 2006-01-09 |
| CN100344624C (zh) | 2007-10-24 |
| CN1761661A (zh) | 2006-04-19 |
| WO2004083201A1 (ja) | 2004-09-30 |
| TWI327910B (enExample) | 2010-08-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2478370C2 (ru) | Стабилизированная фармацевтическая композиция, содержащая доцетаксел | |
| EP0336200B1 (en) | Pharmaceutical compositions of piroxicam in aqueous solutions and process for their preparation | |
| JP6356873B2 (ja) | タキサン系活性成分含有液体組成物及び液体製剤 | |
| JP2018516989A (ja) | ヘッジホッグ阻害性化合物の送達のための局所的製剤及びその使用 | |
| TW202128210A (zh) | 欣得泰乾粉注射劑穩定劑型 | |
| KR101010547B1 (ko) | 알기닌아미드류를 함유하는 의약 제제 | |
| CA2798575C (en) | Pharmaceutical composition of ibuprofen for injection | |
| EP3984524A1 (en) | Ornidazole injection and s-ornidazole injection | |
| JP3917820B2 (ja) | オザグレルナトリウム含有注射液およびその安定化方法 | |
| JP2010536906A (ja) | G−csfの液体製剤 | |
| JP2006008696A (ja) | アルギニンアミド類を含有する医薬製剤 | |
| EP4566602A1 (en) | Pharmaceutical composition containing pyrrole gastric acid secretion inhibitor and preparation method therefor | |
| HU191538B (en) | Process for producing pharmaceutical compositions containing acid additional salts of vinca-dimeres | |
| WO2023275157A1 (en) | Aqueous, room-temperature stable rocuronium composition | |
| CN100512810C (zh) | 预混的乙胺碘呋酮胃肠外溶液及其制备方法 | |
| CN100467024C (zh) | 氯诺昔康注射用组合物及其制备方法 | |
| UA75620C2 (en) | Stable pharmaceutical form of paclitaxel and method for the preparation thereof | |
| US20210228527A1 (en) | Busulfan composition, preparation method therefor and application thereof | |
| JP3242924B2 (ja) | 調製済みのアゾセミド(azosemide)注射液 | |
| JP2013216645A (ja) | 炭酸ナトリウム含有シベレスタットナトリウム水和物凍結乾燥製剤 | |
| WO2017198224A1 (zh) | 一种瑞马唑仑的药物组合物 | |
| WO2024078529A1 (zh) | 一种普那布林胶束组合物及其制备方法 | |
| JPH10287569A (ja) | アシクロビル又はその塩の輸液型キット注射剤 | |
| WO2014007239A1 (ja) | アムホテリシンb含有組成物 | |
| EA048164B1 (ru) | Стабильная лекарственная форма цетрореликса ацетата для парентерального введения |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
Patent event date: 20050916 Patent event code: PA01051R01D Comment text: International Patent Application |
|
| PG1501 | Laying open of application | ||
| N231 | Notification of change of applicant | ||
| PN2301 | Change of applicant |
Patent event date: 20080418 Comment text: Notification of Change of Applicant Patent event code: PN23011R01D |
|
| A201 | Request for examination | ||
| PA0201 | Request for examination |
Patent event code: PA02012R01D Patent event date: 20080430 Comment text: Request for Examination of Application |
|
| N231 | Notification of change of applicant | ||
| PN2301 | Change of applicant |
Patent event date: 20080624 Comment text: Notification of Change of Applicant Patent event code: PN23011R01D |
|
| E902 | Notification of reason for refusal | ||
| PE0902 | Notice of grounds for rejection |
Comment text: Notification of reason for refusal Patent event date: 20100603 Patent event code: PE09021S01D |
|
| E701 | Decision to grant or registration of patent right | ||
| PE0701 | Decision of registration |
Patent event code: PE07011S01D Comment text: Decision to Grant Registration Patent event date: 20101129 |
|
| GRNT | Written decision to grant | ||
| PR0701 | Registration of establishment |
Comment text: Registration of Establishment Patent event date: 20110118 Patent event code: PR07011E01D |
|
| PR1002 | Payment of registration fee |
Payment date: 20110118 End annual number: 3 Start annual number: 1 |
|
| PG1601 | Publication of registration | ||
| FPAY | Annual fee payment |
Payment date: 20131218 Year of fee payment: 4 |
|
| PR1001 | Payment of annual fee |
Payment date: 20131218 Start annual number: 4 End annual number: 4 |
|
| FPAY | Annual fee payment |
Payment date: 20141230 Year of fee payment: 5 |
|
| PR1001 | Payment of annual fee |
Payment date: 20141230 Start annual number: 5 End annual number: 5 |
|
| FPAY | Annual fee payment |
Payment date: 20151217 Year of fee payment: 6 |
|
| PR1001 | Payment of annual fee |
Payment date: 20151217 Start annual number: 6 End annual number: 6 |
|
| FPAY | Annual fee payment |
Payment date: 20161220 Year of fee payment: 7 |
|
| PR1001 | Payment of annual fee |
Payment date: 20161220 Start annual number: 7 End annual number: 7 |
|
| FPAY | Annual fee payment |
Payment date: 20171219 Year of fee payment: 8 |
|
| PR1001 | Payment of annual fee |
Payment date: 20171219 Start annual number: 8 End annual number: 8 |
|
| FPAY | Annual fee payment |
Payment date: 20181226 Year of fee payment: 9 |
|
| PR1001 | Payment of annual fee |
Payment date: 20181226 Start annual number: 9 End annual number: 9 |
|
| FPAY | Annual fee payment |
Payment date: 20191217 Year of fee payment: 10 |
|
| PR1001 | Payment of annual fee |
Payment date: 20191217 Start annual number: 10 End annual number: 10 |
|
| PR1001 | Payment of annual fee |
Payment date: 20201216 Start annual number: 11 End annual number: 11 |
|
| PR1001 | Payment of annual fee |
Payment date: 20211215 Start annual number: 12 End annual number: 12 |
|
| PR1001 | Payment of annual fee |
Payment date: 20231218 Start annual number: 14 End annual number: 14 |
|
| PC1801 | Expiration of term |
Termination date: 20240919 Termination category: Expiration of duration |